Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
Sarcoma
•
Medical Oncology
How do you approach adjuvant therapy for resected Stage I Ewing sarcoma of the kidney, and what chemotherapy regimen and cycle duration do you recommend?
Related Questions
How would you approach adjuvant treatment in a patient with completely resected undifferentiated pleomorphic sarcoma of the chest wall that recurred after 2 years, initially treated with neoadjuvant radiation and resection?
How do you sequence treatment for a patient following R2 resection of a large extremity leiomyosarcoma who has small lung nodules concerning for metastatic disease, but not yet biopsy proven?
Would you offer adjuvant systemic therapy for recurrent fallopian tube leiomyosarcoma after resection of an isolated liver metastasis that presented within 1 year from primary surgery?
How do you approach an otherwise healthy patient with an incidental 1 mm GIST involving the serosal surface in terms of staging workup, EGD, and surveillance?
How would you manage an epidural spinal metastasis causing cord compression from rhabdomyosarcoma?
What is the recommended approach for a 7 cm x 5 cm paraspinal subcutaneous desmoid tumor (T6 to T9) incidentally detected on PET CT during NSCLC monitoring, with confirmed growth over 18 months?
Would you recommend post operative radiation in an adult patient with a thoracic spine osteosarcoma?
Would you use neoadjuvant TKI or neoadjuvant radiation for a large chest wall sarcoma with an NTRK fusion on NGS?
How do you approach a patient with undifferentiated pleomorphic sarcoma encasing the spinal cord post radiation for neurological deficits for further management?
What factors do you consider when choosing between vimseltinib and pexidartinib for tenosynovial giant cell tumor (TGCT) patients?
